Blood thrombopoietin levels in clonal thrombocytosis and reactive thrombocytosis

American Journal of Medicine

Volumn 104, Issue 5, 1998, Pages 451-455

  Wang, Jen C ^a   Chen, Chi ^a   Novetsky, Allan D ^a   Lichter, Stephen M ^a   Ahmed, Fakhiuddin ^a   Friedberg, Neal M ^a  

^a BROOKDALE UNIVERSITY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THROMBOPOIETIN;

ADULT; ARTICLE; DIFFERENTIAL DIAGNOSIS; HUMAN; IRON DEFICIENCY ANEMIA; MAJOR CLINICAL STUDY; MEGAKARYOCYTE; PRIORITY JOURNAL; SICKLE CELL ANEMIA; THROMBOCYTE COUNT; THROMBOCYTOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA, IRON-DEFICIENCY; ANEMIA, SICKLE CELL; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MYELOID METAPLASIA; NEOPLASMS; PLATELET COUNT; POLYCYTHEMIA VERA; REPRODUCIBILITY OF RESULTS; THROMBOCYTHEMIA, HEMORRHAGIC; THROMBOCYTOSIS; THROMBOPOIETIN;

EID: 0032076554     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(98)00090-4     Document Type: Article

References (34)

1. May 1998 THE AMERICAN JOURNAL OF MEDICINE® Volume 104 1. Morowitz DA, Allen LW, Kirsner JB. Thrombocytosis in chronic inflammatory bowel disease. Ann Intern Med. 1968;18:1013-1021.
2. 2. Frenkel EP. Southwestern Internal Medicine Conference: The clinical spectrum of thrombocytosis and thrombocythemia. Am J Med Sci. 1991;301(1):69-80.
3. 3. Levin J, Conley CL. Thrombocytosis associated with malignancy. Arch Intern Med. 1964;114:497-500.
4. 4. Colombi M, Radaelli F, Zocchi L, Maiolo AT. Thrombotic and hemorrhagic complications in essential thrombocythemia: a retrospective study of 103 patients. Cancer. 1991;67:2926-2930.
5. 5. Cortelazzo S, Viero P, Finazzi G, et al. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol. 1990;3:556-562.
6. 6. Burkhardt R, Bartl R, Jager K, et al. Working classification of chronic myeloproliferative disorders based on histological haematological, and clinical findings. J Clin Pathol. 1986;39:237-252.
7. 7. Kopf I, Swolin B, Weinfeld A. Cytogenetic studies on primary thrombocythaemia. Hereditas. 1982;97:217-220.
8. 8. Schafer AI. Bleeding and thrombosis in the myeloproliferative disorders. Blood. 1984;64:1-12.
9. 9. Dudley JM, Messinezy M, Eridani S, et al. Primary thrombocythaemia: diagnostic criteria and a simple scoring system for positive diagnosis. Br J Haematol. 1989;71:331-335.
10. 10. Fenaux P, Simon M, Caulier MT, et al. Clinical course of essential thrombocythemia in 147 cases. Cancer. 1990;66:549-556.
11. 11. Chistolini A, Mazzucconi MG, Ferrari A, et al. Essential thrombocythemia: a retrospective study on the clinical course of 100 patients. Haematologica. 1990;75:537-540.
12. 12. deSauvage FJ, Mass PE, Spencer SD, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-mpl ligand. Nature. 1994;369:533-538.
13. 13. Kuter DJ, Beeler DL, Rosenburg RD. The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci USA. 1994;91:11104-11108.
14. 14. Bartley TD, Bogenerger J, Hunt P, et al. Identification and cloning of a megakaryocyte growth and develop-ment factor that is a ligand for the cytokine receptor mpl. Cell. 1994;77:1117-1124.
15. 15. Lok S, Kaushansky K, Holly RD, et al. Cloning and expression of murine thrombopoietin cDNA and /timulation of platelet production in vivo. Nature. 1994;369:565-568.
16. 16. Kaushansky K, Lok S, Holly RD, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl Ligand thrombopoietin. Nature. 1994;369:568-571.
17. 17. Wendling F, Maraskovsky E, Debili N, et al. cMpl Ligand is a humoral regulator of megakaryocytopoiesis. Nature. 1994;369:571-578.
18. 18. Tefferi A, Silverstein MN, Hoagland HC. Primary thrombocythemia. Semin Oncol. 1995;22:334-340.
19. 19. Wang JC, Chen C, L-H Lou, Mora M. Blood thrombopoietin, IL-6, IL-11 levels in patients with agnogenic myeloid metaplasia. Leukemia. 1997;11:1827-1832.
20. 20. Nichol JL. Serum levels of thrombopoietin in health and disease. In: Kuter DJ, Hunt P, Sheridan W, Zucker-Franklin D, eds. Thrombopoiesis and Thrombopoietins. Totowa, New Jersey: Human Press; 1997;359-375.
21. 21. Choe EI, Kasabian AK, Kolker AR, et al. Thrombocytosis after major lower extremity trauma: mechanism and possible role in free flap failure. Ann Plastic Surg. 1996;36:489-494.
22. 22. Chang M, Yu S, Meng G, et al. Differential mechanisms in the regulation of endogenous levels of thrombopoietin and Interleukin-11 during thrombocytopenia: insight into the regulation of platelet production. Blood. 1996;88:3354-3362.
23. 23. Kosugi S, Kirata Y, Tomiyama Y, et al. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura. Br J Haematol. 1996;93:704-706.
24. 24. Kuter DJ, Rosenberg RD. The reciprocal relationship of thrombopoietin (c-MPL ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood. 1995;85: 2720-2730.
25. 25. McCarty JM, Sprugel KH, Fox NE, et al. Murine thrombopoietin mRNA levels are modulated by platelet count. Blood. 1995;86: 3668-3675.
26. 26. Alexander WS, Roberts AW, Nicola NA, et al. Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietin receptor c-Mpl. Blood. 1996;87:2162-2170.
27. 27. Cohen-Solal K, Villeval J-L, Titeux M, et al. Constitutive expression of MpI ligand transcripts during thrombocytopenia or thrombocy-tosis. Blood. 1996;88:2578-2584.
28. 28. Stoffel R, Wiestner S, Skoda RC. Thrombopoietin in thrombocytopenic mice: evidence against regulation at the nRNA level and for a direct regulatory role of platelets. Blood. 1996;87:567-573.
29. 29. Li J, Xia Y, Kuter DJ. Analysis of the thrombopoietin receptor (MPL) on platelets from normal and essential thrombocythemia (ET) patients. Blood. 1996;88:545a. Abstract.
30. 30. Best D, Hornkohl A, Selesi D, et al. Evaluation of biological activity, molecular weight and circulating levels of TO in plasma from normal donors and patients with abnormal platelet numbers. Exp Hematol. 1996;24:1069. Abstract.
31. 31. Hollen CW, Henthorn J, Koziol JA, Burnstein SA. Elevated serum interleukin-6 levels in patients with reactive thrombocytosis. Br J Haematol. 1991;79:286-290.
32. 32. Hollen CW, Henthorn J, Koziol JA, Burnstein SA. Serum interleukin-6 levels in patients with thrombocytosis. Leukem Lymphoma. 1992;8:235-241.
33. 33. Gastl G, Plante M, Finstad CL, et al. High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer. Br J Haematol. 1993;83:433-441.
34. 34. Tefferi A, Ho TC, Ahmann GJ, et al. Plasma interleukin-6 and C-Reactive protein levels in reactive versus clonal thrombocytosis. Am J Med. 1994;97:374.